We are Sorry, This Page doesn't Exist
Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study
Gilead Sciences Inc (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: read more.....»»
Baird Analyst Says "Don"t Give Up" Yet On Gilead"s Remdesivir
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) fell Thursday afternoon in reaction to a disappointing report on an early readout for its remdesivir therapy, but investors should not "give up on this Latest Ratings fo.....»»
Small-Cap Biotechs Developing Novel Gene Therapies Could Become Targets of Big Pharma
The acquisition of Kite Pharmaceuticals by Gilead and Juno Therapeutics by Celgene may lead to more acquisitions of CAR-T gene therapy companiesRelated Stocks: GILD, NVS, CELG, MBIO, CYAD, CLLS, PFE, BLCM,.....»»
Clovis Breaks Into Europe With EMA Approval
Clovis Oncology shares saw a bump early on Thursday after the company announced that the European Medicines Agency has validated its application for a Type 2 variation to the marketing authorization........»»
Gilead"s (GILD) Harvoni and Descovy Get Approval in China
Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China. Gilead Sciences, Inc. GILD announced that the National Medical P.....»»
Why Scopus BioPharma"s Stock Is Surging Today
Scopus BioPharma (NASDAQ:SCPS) shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. read more.....»»
Gilead Sciences Stock Appears To Be Modestly Undervalued
Related Stocks: GILD,.....»»
Gilead"s virology drug head named CEO of East Coast biotech AlloVir
Dr. Diana Brainard, a 10-year veteran of Gilead Sciences Inc. who currently heads up the company's broad virology drug pipeline, will take over as CEO of a young cell therapy company backed by her soon-to-be former employer. Starting May 17, Brain.....»»
Gilead, Merck to develop long-acting HIV therapy treatment, WSJ reports
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Gritstone Oncology shares soar 44% premarket on news of collaboration with Gilead to develop HIV therapy
Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to us.....»»
GaN-on-SiC application to 5G base stations ramping up in US, Europe
Vendors in the US and Europe are ramping up application of third-generation semiconductor materials including SiC (silicon carbide) and GaN to 5G base stations and EVs, according to industry sources......»»
Agenus: FDA accepts IND application for allogeneic iNKT therapy, agenT-797
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
OncoSec"s Tavo granted ATMP certification in Europe for application in melanoma
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
June 26th Options Now Available For Gilead Sciences (GILD)
Stock Options Channel.....»»
Here’s Why Tao Value Loves Gilead Sciences (GILD) Stock
Tao Value recently released its Q1 2020 Investor Letter, a copy of which you can download here. The fund posted a return of -12.96% for t.....»»
Gilead Works To "Maximize Global Supply" Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss
Gilead Sciences, Inc. (NASDAQ: GILD) recently received emergency use authorization from the FDA for its coronavirus treatment candidate remdesivir. read more.....»»
"Remdesivir" To Be Available For Coronavirus Patients This Week, Gilead CEO Says
Gilead Sciences, Inc. (NASDAQ: GILD) chief executive officer Daniel O'Day told CBS on Sunday that the company's Remdesivir drug wil read more.....»»
Gilead has yet to set a price for the coronavirus treatment remdesivir, but an influential drug pricing watchdog says it could be worth up to $4,500 per patient (GILD)
Reuters Gilead Sciences could be.....»»
FDA grants Gilead’s remdesivir emergency authorization for COVID-19 treatment
The Food and Drug Administration on Friday granted an emergency use authorization to Gilead Sciences Inc.’s remdesivir, a decade-old experimental therapy first tested on Ebola disease patients, as a COVID-19 treatment......»»
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
Gilead Sciences, Inc. (NASDAQ: GILD) reported an.....»»